Scholar Rock Holding Corporation (NASDAQ:SRRK) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Scholar Rock ...

Overview - As demand for GLP-1 drugs continues to skyrocket, federal and state agencies are turning their attention to the GLP-1 ...

Recent research suggests a possible increased risk of serious eye conditions, such as non-arteritic anterior ischaemic optic ...

The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...

Two studies were conducted to verify concerns about diabetic retinopathy that were raised during initial trials of ...

Study links weight-loss drugs to serious eye conditions and vision loss - Researchers suggest all diabetes patients on weight-loss drugs should be regularly screened and monitored for potential eye co ...

New studies indicate that weight-loss drugs may lead to serious eye diseases and vision loss in some individuals, prompting ...

The risk of new-onset diabetic retinopathy (DR) increased slightly, but significantly, in patients taking GLP-1 receptor ...

The partnership means that Apple's fitness and wellness service will be made available to all members who enrol onto ...

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

The Government has announced a pilot to test new ways to support patients living with obesity, in a bid to ease pressures on ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...